Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Remain Informed about the Most recent Open Record Extra Offers - 2Excited visitors for NASA's moon launch jockey for prime views
- 3Emergency services search for five people last seen in missing Jeep
- 4IDF kills four terrorists equipped with weapons, surveillance gear near Gaza's Yellow Line
- 5The 25 Most Notable Style Crossroads in History
- Are Saturn's rings made of a lost, shattered moon? New evidence arises for the case
- Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- Report: Thailand strikes deal with Iran for safe passage of Hormuz
- South Carolina's measles outbreak reaches 434 cases
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- Tech Patterns: Contraptions That Will Shape What's in store
- More parents refusing this shot that prevents serious bleeding at birth
- The Incomparable Advanced cameras: Which One Will Win?
- Choosing the Ideal Bed for Quality Rest and Solace
